Skip to Navigation Skip to Search Skip to Content
Search All Centers

ESMO 2017 Lung Cancer Research Update

Read Transcript Download/Print Transcript
View next

Published on September 22, 2017

Lung cancer has been the cancer with the most exciting news at the European Society of Medical Oncology (ESMO) conference held in Madrid in September 2017. Dr. Frank Griesinger, Head of Clinical Oncology at Pius-Hospital (Oldenburg, Germany), comments on the studies that will bring more hope to patients. In some cases, results presented at ESMO 17 will change clinical practice for lung cancer patients. 

This interview was recorded at the European Society of Medical Oncology (ESMO) congress held in Madrid (September 2017). Lung cancer videos recorded at ESMO 17 are part of an educational program by the Patient Empowerment Foundation (PEF). We thank AstraZeneca for their support.

Featuring

Transcript | ESMO 2017 Lung Cancer Research Update

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Dr. Griesinger:

So I think the most significant new information is probably the FLAURA Trial, the FLAURA Trial that will be presented today, and it seems that the third-generation osimertinib (Tagrisso) is better in PSS than the first-generation EGFR, TKIs.  So we haven't seen the data yet, but it seems that probably osimertinib will become most likely the new standard of care for EGFR-mutated patients. 

The next really big issue is the immune therapy in stage III after radiochemotherapy.  This is the first trial that obviously shows a benefit for the patients if you give consolidation therapy with durvalumab (Imfinzi), so an immune checkpoint inhibitor.  I think then we have some pretty good new stuff on also immune therapy issues like some data on atezolizumab (Tecentriq), some data on tumor mutational burden, and so I think these are the most important highlights of the ESMO.  

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

View next